International Pharmaceutical Aerosol Consortium on Regulation & Science
The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) is an international non-profit association comprised of companies that develop, manufacture, market, and support research and development of inhaled and nasal drugs and biologics (INDBs). IPAC-RS seeks to advance the science, and especially the regulatory science, of these products by collecting and analyzing data, conducting joint research and development projects, and engaging the wider community. Representing this industry sector for more than 25 years, IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of its research through conferences, technical journals, webinars, and discussions with regulatory bodies.
SAVE THE DATES
IPAC-RS 2026 Nasal Innovation Forum
Wednesday-Thursday, September 16-17, 2026
This 1.5-day in-person event will continue the discussions on issues presented at and lessons learned from the 2025 NIF with industry leaders, scientists and regulators exploring topics in: Device Selection, Manufacturing Best Practices, Pre IND to CTM Roadmap, Regulatory Pathway, Patient Perspectives and an Investor Discussion Panel.
Visit the Forum webpage for more details.
Now Accepting Poster Abstracts. Visit the Forum webpage for details.
IPAC-RS Roundtable Webinar Series
In 2021, IPAC-RS launched a webinar series presented by SMEs in the pharmaceutical sciences, which enabled attendees the opportunity to learn about the latest research and regulatory trends. See the IPAC-RS Roundtables webpage for links to presentations and recordings for the webinars held in 2021 - 2025.
IPAC-RS September 2024 Workshop:
Inhaled Biologics: Preparing for a Future Beyond Small Molecules
This hybrid event brought together industry experts to discuss the key challenges facing developers of inhaled and nasal biologics.
Presentations and recordings are now available on the workshop webpage.
IPAC-RS representatives contributed to the planning of and presented at the CRCG Workshop: Navigating the Transition to Low Global Warming Potential Propellants held on December 4-5, 2024.
Ann Purrington (Kindeva) presented An Introduction to the IPAC-RS Scenarios - Transition to LGWP Propellants in MDIs: Proposed Pathways to U.S. FDA Approval and Richard Lostritto, Ph.D. (Consultant/IPAC-RS Science Advisor) and Helen Strickland (GSK) presented on Statistical Considerations for the In Vitro Comparisons of Critical Product Performance Attributes for an Approved MDI Product Transitioning to LGWP Propellant.
Podium presentations and recordings are now available at the weblink above.
News and Events
January 2026
IPAC-RS Nasal Innovation Forum
Advancing Science, Shaping the Future of Nasal Drug Delivery
Thursday - Friday, September 18-19, 2025
This 1.5-day in-person event brought together industry leaders, regulatory experts, and scientific pioneers to explore the complexities of nasal drug development. This forum provided attendees a unique opportunity to engage in thought-provoking discussions, gain insights from expert speakers, and participate in collaborative roundtable sessions.
Visit the Forum webpage for more details. A Summary Report and Audience Feedback is now available.
Presentations/Recordings are now available to the general public on the Forum webpage.
December 2025
The IPAC-RS GRRO Alternate Propellants Working Group prepared a white paper Opportunities to Facilitate the Transition of pMDIs to Third-Generation Propellants available for download.
March 2025
We encourage you to take a look at the IPAC-RS 2024 Year in Review!
The report highlights the impressive work IPAC-RS accomplished in 2024.
